As of 22 Sept 2026, Cohance Lifesciences Ltd share price is ₹460.60. The stock opened at ₹460.60 and had closed at ₹438.05 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹267.85 and a high of ₹917.50. In terms of performance, Cohance Lifesciences Ltd share price has increased by 53.18% over the past six months and has decreased by 48.75% over the last year.
COHANCE Stock Price Chart
Cohance Lifesciences Ltd Overview
About COHANCE
Cohance Lifesciences engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Cohance Lifesciences Ltd Historical Performance
Cohance Lifesciences Ltd Fundamentals
Cohance Lifesciences Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 2,075.23 | 2,569.27 | 1,107.96 | 1,374.63 | 1,508.01 |
| EBITDA | 469.67 | 833.27 | 462.47 | 635.24 | 767.78 |
| Net Profit | 228.71 | 491.18 | 296.47 | 432.60 | 558.10 |
| EPS | 5.98 | 12.89 | 11.65 | 16.99 | 21.92 |
Cohance Lifesciences Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 429.53 |
| Resistance 1 (R1) | 446.43 |
| Pivot Point | 437.92 |
Cohance Lifesciences Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 09-Sep-2022 | 02-Sep-2022 | 12-Sep-2022 | Interim | ₹1.00 |
| 09-Sep-2022 | 02-Sep-2022 | 12-Sep-2022 | Special | ₹5.00 |
| 13-May-2022 | 09-May-2022 | 17-May-2022 | Interim 2 | ₹1.00 |
| 13-May-2022 | 09-May-2022 | 17-May-2022 | Special | ₹1.00 |
| 15-Feb-2022 | 08-Feb-2022 | 16-Feb-2022 | Interim | ₹1.00 |
COHANCE Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| Vivek Sharma | Chairman |
| Vinod Padikkal | Non Executive Independent Director |
| K G Ananthakrishnan | Non Executive Independent Director |
Cohance Lifesciences Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,868.90+1.72% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,410.50+0.38% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,970.00+2.69% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Cohance Lifesciences Ltd today is ₹460.60 on NSE and ₹460.60 on BSE.
- The 52-week high of Cohance Lifesciences Ltd is ₹917.50, while the 52-week low is ₹267.85.
- The current market capitalisation of Cohance Lifesciences Ltd is approximately ₹17,622 crore.
- The P/E (Price-to-Earnings) ratio of Cohance Lifesciences Ltd is 43.97. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Cohance Lifesciences Ltd is 3.01. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Cohance Lifesciences Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for COHANCE on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Cohance Lifesciences Ltd has delivered a return of approximately -13.97%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Cohance Lifesciences Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 57.49% promoters, -11.71% FIIs, 20.09% DIIs, and 7.71% public shareholders.
Download TradeMobi App
- Real-Time Market Data
- Advanced Trading Tools
- Expert-Backed Research
